Skip to main content
Equibles

Beneficial ownership — 13D / 13G

85,680 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Dapice Joshua J. RVMD Revolution Medicines, Inc. 13G 6.2% 3y
First Trust Capital Management L.P. FEXD Fintech Ecosystem Development Corp. Class A Common Stock 13G/A 9.68% 3y
COMPASS GROUP LLC VTRU Vitru Limited Common Shares 13G/A 14.15% 3y
WELLINGTON MANAGEMENT GROUP LLP AGIO Agios Pharmaceuticals, Inc. 13G/A 3.95% 3y
John P. Szabo, Jr. GAIA Gaia, Inc 13G 9% 3y
Versant Venture Capital VI, L.P. BDTX Black Diamond Therapeutics, Inc. 13D/A 8.4% 3y
Versant Venture Capital VI, L.P. GLUE Monte Rosa Therapeutics, Inc. 13D/A 13.7% 3y
Versant Venture Capital VI, L.P. TPST Tempest Therapeutics, Inc. 13D/A 15.9% 3y
Versant Venture Capital VI, L.P. PASG Passage BIO, Inc. 13D/A 7.3% 3y
John P. Szabo, Jr. INVE INVE Technologies, Inc. 13G 8% 3y
TENOR CAPITAL MANAGEMENT Co., L.P. NOGN Nogin, Inc. Common Stock 13G 5.03% 3y
Jelena Puzovic ATER Aterian, Inc. 13G/A 0.07% 3y
Artisan Topco LP AVID Avid Technology Inc 13D/A 100% 3y
Exor N.V. CLVT Clarivate PLC 13D/A 7.37% 3y
Patel Chirag K. AMRX Amneal Pharmaceuticals, Inc. 13D/A 7.1% 3y
STADIUM CAPITAL MANAGEMENT LLC SNBRQ Sleep Number Corp 13D/A 9% 3y
Patel Dipan AMRX Amneal Pharmaceuticals, Inc. 13D/A 8.8% 3y
Atlas Investissement SAS TIGO Millicom International Cellular SA 13D/A 28.2% 3y
Patel Tushar Bhikhubhai AMRX Amneal Pharmaceuticals, Inc. 13D/A 17.5% 3y
Jacobsen Per A. BLIN Bridgeline Digital, Inc. 13G/A 6.5% 3y
Gautam Patel AMRX Amneal Pharmaceuticals, Inc. 13D/A 10% 3y
TORO 18 HOLDINGS LLC UEIC Universal Electronics Inc 13D/A 10.9% 3y
Patel Chintu AMRX Amneal Pharmaceuticals, Inc. 13D/A 8.3% 3y
Family Trading Inc. TOPS Top Ships Inc. 13D/A 60.79% 3y
Rubric Capital Management LP MREO Mereo BioPharma Group plc 13D/A 13.63% 3y
BRIGADE CAPITAL MANAGEMENT, LP GFR Greenfire Resources Ltd. 13D/A 8.8% 3y
Saba Capital Management, L.P. BMEZ BlackRock Health Sciences Term Trust 13D/A 11.31% 3y
Bandera Partners LLC JYNT JOINT Corp 13D/A 26.7% 3y
Saba Capital Management, L.P. SABA Saba Capital Income & Opportunities Fund II 13D/A 30.86% 3y
Peter J. Werth CING Cingulate Inc. 13D/A 19.99% 3y
Qatar Investment Authority NBTX Nanobiotix S.A. 13G 8.6% 3y
Jerome F. McAleer LMDX LumiraDx Limited Common Shares 13D/A 9.3% 3y
Bellevue Capital Partners, LLC NYC American Strategic Investment Co. 13D/A 46.3% 3y
David Scott LMDX LumiraDx Limited Common Shares 13D/A 10.8% 3y
First Frontier Capital LLC RMCO Royalty Management Holding Corp 13D 8.2% 3y
LEUTHOLD GROUP, LLC AAPD Direxion Shares ETF Trust 13G/A 13.5% 3y
White River Ventures LLC RMCO Royalty Management Holding Corp 13D 6% 3y
JPMORGAN CHASE & CO TER Teradyne, Inc 13G/A 3.7% 3y
Lumira Capital Investment Management Inc. ENGN enGene Therapeutics Inc. 13D 14.4% 3y
JPMORGAN CHASE & CO GPOR Gulfport Energy Corp 13G/A 3.8% 3y
Travis M. Joyner LOCL Local Bounti Corporation 13D/A 16.1% 3y
Liberty Hill Capital Management, LLC RMCO Royalty Management Holding Corp 13D 9.95% 3y
Wheat Wind Farms LLC LOCL Local Bounti Corporation 13D/A 16.8% 3y
MACKENZIE FINANCIAL CORP STN Stantec Inc 13G 10.01% 3y
JPMORGAN CHASE & CO GLOB Globant S.A. 13G/A 3.7% 3y
PRIMECAP MANAGEMENT CO/CA/ ELAN Elanco Animal Health Inc 13G/A 10.28% 3y
Midwest General Investment Co LLC RMCO Royalty Management Holding Corp 13D 7% 3y
Long Focus Capital Management, LLC ADAPY Adaptimmune Therapeutics PLC 13G 5% 3y
JPMORGAN CHASE & CO ATSG Air Transport Services Group, Inc. 13G/A 3.6% 3y
Orin Hirschman ANVS Annovis Bio, Inc. 13G 5.6% 3y